275 related articles for article (PubMed ID: 25140317)
1. Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer.
Chen DR; Lu DY; Lin HY; Yeh WL
Biomed Res Int; 2014; 2014():532161. PubMed ID: 25140317
[TBL] [Abstract][Full Text] [Related]
2. Peri-foci adipose-derived stem cells promote chemoresistance in breast cancer.
Yeh WL; Tsai CF; Chen DR
Stem Cell Res Ther; 2017 Jul; 8(1):177. PubMed ID: 28750689
[TBL] [Abstract][Full Text] [Related]
3. The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells.
Ryan D; Paul BT; Koziol J; ElShamy WM
Breast Cancer Res; 2019 Apr; 21(1):53. PubMed ID: 31014367
[TBL] [Abstract][Full Text] [Related]
4. PYCR3 modulates mtDNA copy number to drive proliferation and doxorubicin resistance in triple-negative breast cancer.
Zhuang F; Huang S; Liu L
Int J Biochem Cell Biol; 2024 Jun; 171():106581. PubMed ID: 38642827
[TBL] [Abstract][Full Text] [Related]
5. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
6. Embryonic stem cell secreted factors decrease invasiveness of triple-negative breast cancer cells through regulome modulation.
Tarasewicz E; Oakes RS; Aviles MO; Straehla J; Chilton KM; Decker JT; Wu J; Shea LD; Jeruss JS
Cancer Biol Ther; 2018 Apr; 19(4):271-281. PubMed ID: 29053396
[TBL] [Abstract][Full Text] [Related]
7. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
8. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
Front Immunol; 2019; 10():804. PubMed ID: 31105691
[TBL] [Abstract][Full Text] [Related]
9. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
11. Expression of miR-335 in triple-negative breast cancer and its effect on chemosensitivity.
Hao J; Lai M; Liu C
J BUON; 2019; 24(4):1526-1531. PubMed ID: 31646803
[TBL] [Abstract][Full Text] [Related]
12. Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
J Cell Physiol; 2020 Sep; 235(9):6230-6245. PubMed ID: 32017076
[TBL] [Abstract][Full Text] [Related]
13. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.
Cheriyan VT; Muthu M; Patel K; Sekhar S; Rajeswaran W; Larsen SD; Polin L; Levi E; Singh M; Rishi AK
Oncotarget; 2016 Nov; 7(45):73370-73388. PubMed ID: 27687593
[TBL] [Abstract][Full Text] [Related]
14. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
16. Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence.
Lyes MA; Payne S; Ferrell P; Pizzo SV; Hollenbeck ST; Bachelder RE
Breast Cancer Res Treat; 2019 Apr; 174(2):413-422. PubMed ID: 30594967
[TBL] [Abstract][Full Text] [Related]
17. Apigenin by targeting hnRNPA2 sensitizes triple-negative breast cancer spheroids to doxorubicin-induced apoptosis and regulates expression of ABCC4 and ABCG2 drug efflux transporters.
Sudhakaran M; Parra MR; Stoub H; Gallo KA; Doseff AI
Biochem Pharmacol; 2020 Dec; 182():114259. PubMed ID: 33011162
[TBL] [Abstract][Full Text] [Related]
18. Biomimetic nanovesicles made from iPS cell-derived mesenchymal stem cells for targeted therapy of triple-negative breast cancer.
Zhao Q; Hai B; Zhang X; Xu J; Koehler B; Liu F
Nanomedicine; 2020 Feb; 24():102146. PubMed ID: 31884039
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-induced tRNA-derived fragments, novel regulatory factor for doxorubicin resistance in triple-negative breast cancer.
Cui Y; Huang Y; Wu X; Zheng M; Xia Y; Fu Z; Ge H; Wang S; Xie H
J Cell Physiol; 2019 Jun; 234(6):8740-8751. PubMed ID: 30362543
[TBL] [Abstract][Full Text] [Related]
20. Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity.
Bamodu OA; Huang WC; Tzeng DT; Wu A; Wang LS; Yeh CT; Chao TY
Cancer Lett; 2015 Aug; 364(2):125-34. PubMed ID: 25976769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
